Confronting the Remdesivir Shortage
By
Dr. Brian Abrahams
Published May 18, 2020
|
4 min watch
Watch CNBC’s Meg Tirrell talks to Dr. Brian Abrahams, Co-Head of Biotechnology Research at RBC Capital Markets, about the supply of the coronavirus-fighting drug remdesivir.
Dr. Brian Abrahams
Co-Head of Biotechnology Research
Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 16 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.
BiotechnologyBrian AbrahamsRemdesivir
